science

Stop looking for a silver bullet. Start mixing the Long COVID cocktail.

Commentary, Science

·

By

Jon Douglas

–

September 12, 2025

Here’s what keeps me up at night: If some people are finding relief, why aren’t we scaling what might work? And why aren’t we trying multiple interventions at the same time?
Live blog: RECOVER-TLC workshop on new Long COVID clinical trials

Science

·

By

sick times

–

September 9, 2025

Researchers and advocates meet near the National Institutes of Health (NIH) campus this week in Bethesda, Maryland for the second RECOVER-Treating Long COVID (TLC) workshop. The two-day event will offer updates on the NIH’s larger $1.8-billion Long COVID research program, called RECOVER, and announce a new set of clinical trials for the disease.
The crisis is “exasperating”: Long COVID compounds economic hardship in Argentina

Health, International, Science

·

By

Delfina Marchese

–

August 22, 2025

Argentina is facing an invisible Long COVID crisis, marked by a lack of clinics, minimal media attention, no disability insurance to help people with the disease cope with their inability to work, and only a couple of Long COVID studies — all amid a 48% cut to the national health budget under President Javier Milei.
“The field is coming of age”: Long COVID researchers gather in Santa Fe to foster collaboration

Science

·

By

sick times

–

August 19, 2025

Last week, leading Long COVID and infection-association chronic condition (IACC) researchers met in Santa Fe, New Mexico, for the field’s second Keystone Symposia meeting. They were joined by advocates, clinicians, and representatives from pharmaceutical companies for a three-day conference focused on sharing new research and building consensus.
No “easy home runs”: Early Long COVID trials of Paxlovid and monoclonal antibodies failed, but the treatments still have potential

Science

·

By

Betsy Ladyzhets

–

August 12, 2025

While three early clinical trials of these drugs did not find they led to health improvements for participants, further trials are getting more intentional in targeting viral persistence.
Three clinical trials for Long COVID are testing JAK inhibitors to treat immune dysregulation

Science

·

By

Miles W. Griffis

–

August 5, 2025

Three separate trials are testing the immunomodulator drugs abrocitinib (Cibinqo), baricitinib (Olumiant), and upadacitinib (Rinvoq). All are JAK inhibitors, which target specific inflammation pathways.
Clinical trials are testing cancer drug rapamycin for Long COVID and ME

Science

·

By

Felicity Nelson

–

July 29, 2025

Two clinical trials are currently underway in the U.S. to evaluate the effect of rapamycin on Long COVID and myalgic encephalomyelitis (ME) — one at Mount Sinai’s Cohen Center for Recovery from Complex Chronic Illness and another at Simmaron Research.
Berlin Cures’ failed Long COVID clinical trial yields lessons on study design

International, Investigations, Science

·

By

Betsy Ladyzhets

–

July 22, 2025

After advertising a potential Long COVID “cure” in its novel drug, called BC 007 (rovunaptabin), the German start-up Berlin Cures abruptly concluded its phase II clinical trial with a brief press release in November 2024 announcing the study was unsuccessful. The Sick Times spoke with study participants and outside experts and found that, while some…
Live blog: Following the Patient-Led Research Fund summer 2025 webinar

Science

·

By

sick times

–

July 9, 2025

Members of the Patient-Led Research Collaborative (PLRC) and grantees of their $5 million Patient-Led Research Fund will be presenting updates about their work in a webinar today. The virtual event will feature talks sharing new findings about the underlying biology of infection-associated chronic conditions (IACCs), as well as discussions about how patient engagement leads to…
Live blog: Following the Spring 2025 PolyBio Symposium on Long COVID and related diseases

Science

·

By

sick times

–

May 16, 2025

Leading scientists studying Long COVID and related chronic diseases are set to present updates to their work on Friday at the PolyBio Research Foundation’s Spring Symposium. The Sick Times’ team will be following the presentations throughout the day.